Circulating tumor DNA – Current state of play and future perspectives

De Rubis, G; Krishnan, SR; Bebawy, M

Circulating tumor DNA – Current state of play and future perspectives

De Rubis, G

Krishnan, SR Bebawy, M

Permalink

Publication Type:: Journal Article
Citation:: Pharmacological Research, 2018, 136 pp. 35 - 44
Issue Date:: 2018-10-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted ManuscriptAdobe PDF (1.62 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	De Rubis, G https://orcid.org/0000-0001-7088-396X	en_US
dc.contributor.author	Krishnan, SR	en_US
dc.contributor.author	Bebawy, M https://orcid.org/0000-0003-2606-921X	en_US
dc.date.available	2020-05-25T19:03:30Z
dc.date.issued	2018-10-01	en_US
dc.identifier.citation	Pharmacological Research, 2018, 136 pp. 35 - 44	en_US
dc.identifier.issn	1043-6618	en_US
dc.identifier.uri	http://hdl.handle.net/10453/128269
dc.description.abstract	© 2018 Elsevier Ltd Cancer management paradigms are shifting towards a personalized approach thanks to the advent of the -omics technologies. Liquid biopsies, consisting in the sampling of blood and other bodily fluids, are emerging as a valid alternative to circulating tumor biomarkers and tumor tissue biopsies for cancer diagnosis, routine monitoring and prognostication. The content of a liquid biopsy is referred to as the “tumor circulome”. Among its components, circulating tumor DNA (ctDNA), including both cell-free and exosome-associated DNA, is the most widely characterized element. ctDNA analysis has a tremendous capability in the diagnostic arena. Its potential has been demonstrated at each level of disease staging and management and supported by a recent FDA approval for companion diagnostic, and the investments being made by pharmaceutical companies in this sector are numerous. The approaches available for ctDNA analysis allow both quantitative and qualitative studies and range from PCR and dPCR-mediated single/multiple gene mutational assessment to whole genome next generation sequencing and methylation mapping. Although the principal object of a liquid biopsy is blood, other body fluids such as urine and saliva show potential as complementary DNA sources for tumor analysis. In this review we provide a synopsis on the state of play of current ctDNA application. We discuss the clinical significance of ctDNA analysis and review the state of the art of technologies being currently developed to this aim. We also discuss the current issues limiting ctDNA application and highlight the promising approaches being developed to overcome these.	en_US
dc.relation.ispartof	Pharmacological Research	en_US
dc.relation.isbasedon	10.1016/j.phrs.2018.08.017	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Neoplasms	en_US
dc.subject.mesh	Liquid Biopsy	en_US
dc.subject.mesh	Circulating Tumor DNA	en_US
dc.title	Circulating tumor DNA – Current state of play and future perspectives	en_US
dc.type	Journal Article
utslib.citation.volume	136	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	136	en_US

Abstract:

© 2018 Elsevier Ltd Cancer management paradigms are shifting towards a personalized approach thanks to the advent of the -omics technologies. Liquid biopsies, consisting in the sampling of blood and other bodily fluids, are emerging as a valid alternative to circulating tumor biomarkers and tumor tissue biopsies for cancer diagnosis, routine monitoring and prognostication. The content of a liquid biopsy is referred to as the “tumor circulome”. Among its components, circulating tumor DNA (ctDNA), including both cell-free and exosome-associated DNA, is the most widely characterized element. ctDNA analysis has a tremendous capability in the diagnostic arena. Its potential has been demonstrated at each level of disease staging and management and supported by a recent FDA approval for companion diagnostic, and the investments being made by pharmaceutical companies in this sector are numerous. The approaches available for ctDNA analysis allow both quantitative and qualitative studies and range from PCR and dPCR-mediated single/multiple gene mutational assessment to whole genome next generation sequencing and methylation mapping. Although the principal object of a liquid biopsy is blood, other body fluids such as urine and saliva show potential as complementary DNA sources for tumor analysis. In this review we provide a synopsis on the state of play of current ctDNA application. We discuss the clinical significance of ctDNA analysis and review the state of the art of technologies being currently developed to this aim. We also discuss the current issues limiting ctDNA application and highlight the promising approaches being developed to overcome these.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/128269